ECSP077281A - Conjugados de hormona del crecimiento humana y polietilenglicol ramificado con glicerol, proceso para su preparación y métodos de uso de los mismos - Google Patents

Conjugados de hormona del crecimiento humana y polietilenglicol ramificado con glicerol, proceso para su preparación y métodos de uso de los mismos

Info

Publication number
ECSP077281A
ECSP077281A EC2007007281A ECSP077281A ECSP077281A EC SP077281 A ECSP077281 A EC SP077281A EC 2007007281 A EC2007007281 A EC 2007007281A EC SP077281 A ECSP077281 A EC SP077281A EC SP077281 A ECSP077281 A EC SP077281A
Authority
EC
Ecuador
Prior art keywords
growth hormone
human growth
glicerol
ramified
conjugates
Prior art date
Application number
EC2007007281A
Other languages
English (en)
Inventor
Rory F Finn
Ned R Siegel
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35708806&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP077281(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Publication of ECSP077281A publication Critical patent/ECSP077281A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a la PEGlilación de la hormona del crecimiento humano (hGh) usando un PEG ramificado con glicerol. La presente invención también se refiere a procesos para la PEGilación de hGH. Además, la presente invención se refiere a composiciones farmacéuticos que comprenden la hGH PEGilada. Otra realización es el uso de hGH PEGilada para el tratamiento de trastornos del crecimiento y del desarrollo.
EC2007007281A 2004-08-31 2007-02-27 Conjugados de hormona del crecimiento humana y polietilenglicol ramificado con glicerol, proceso para su preparación y métodos de uso de los mismos ECSP077281A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60594504P 2004-08-31 2004-08-31

Publications (1)

Publication Number Publication Date
ECSP077281A true ECSP077281A (es) 2007-03-29

Family

ID=35708806

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2007007281A ECSP077281A (es) 2004-08-31 2007-02-27 Conjugados de hormona del crecimiento humana y polietilenglicol ramificado con glicerol, proceso para su preparación y métodos de uso de los mismos

Country Status (24)

Country Link
EP (1) EP1789092A2 (es)
JP (1) JP2008511610A (es)
KR (1) KR20070042567A (es)
CN (1) CN101010105A (es)
AP (1) AP2007003919A0 (es)
AR (1) AR050851A1 (es)
AU (1) AU2005278903A1 (es)
BR (1) BRPI0515118A (es)
CA (1) CA2577999A1 (es)
CR (1) CR8942A (es)
EA (1) EA200700380A1 (es)
EC (1) ECSP077281A (es)
GT (1) GT200500235A (es)
IL (1) IL181085A0 (es)
MA (1) MA28908B1 (es)
MX (1) MX2007002441A (es)
NL (1) NL1029828C2 (es)
NO (1) NO20071322L (es)
PE (1) PE20060654A1 (es)
TN (1) TNSN07078A1 (es)
TW (1) TW200621291A (es)
UY (1) UY29088A1 (es)
WO (1) WO2006024953A2 (es)
ZA (1) ZA200701802B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7495087B2 (en) 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
ATE375363T1 (de) 1997-07-14 2007-10-15 Bolder Biotechnology Inc Derivate des wachstumshormons und verwandte proteine
AU775937B2 (en) 1999-01-14 2004-08-19 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
EP1834963A1 (en) * 2006-03-13 2007-09-19 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
JP2009536963A (ja) * 2006-05-12 2009-10-22 ドン・ア・ファーム・カンパニー・リミテッド ポリエチレングリコール−インターフェロンα結合体
JP2008069073A (ja) * 2006-09-12 2008-03-27 Yokohama Tlo Co Ltd ラクトフェリン複合体及びその製造方法
KR101079993B1 (ko) * 2006-11-17 2011-11-04 동아제약주식회사 폴리에틸렌글리콜 과립구 콜로니 자극인자 접합체
CL2008002399A1 (es) 2007-08-16 2009-01-02 Pharmaessentia Corp Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
EP2300501B1 (en) * 2008-07-23 2014-08-20 Hanmi Science Co., Ltd. A polypeptide complex comprising non-peptidyl polymer having three functional ends
JP5639585B2 (ja) 2008-07-31 2014-12-10 ファーマエッセンティア コーポレイション ペプチド−ポリマー共役体
US8535655B2 (en) 2008-10-10 2013-09-17 Polyactiva Pty Ltd. Biodegradable polymer—bioactive moiety conjugates
SI2340271T1 (sl) * 2008-10-10 2019-08-30 Polyactiva Pty Ltd. Konjugati polimer-bioaktivnega sredstva
WO2010040188A1 (en) * 2008-10-10 2010-04-15 The Bionic Ear Institute Biodegradable polymer - bioactive moiety conjugates
DK3178835T3 (da) 2009-02-03 2019-06-24 Amunix Pharmaceuticals Inc Forlængede rekombinante polypeptider og sammensætninger omfattende samme
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
WO2011015649A1 (en) 2009-08-06 2011-02-10 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
CN101831067A (zh) * 2010-05-31 2010-09-15 王二新 聚乙二醇脂类缀合物及其在制备药物中的应用
EP2446898A1 (en) 2010-09-30 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Use of growth hormone to enhance the immune response in immunosuppressed patients
CN102367290B (zh) * 2011-04-26 2013-05-08 厦门赛诺邦格生物科技有限公司 链官能化的多级支化聚乙二醇及其合成方法
CN104302408B (zh) * 2012-02-27 2016-12-14 阿穆尼克斯运营公司 Xten缀合组合物和制造其的方法
EP2947111B1 (en) * 2013-01-17 2018-03-07 Xiamen Sinopeg Biotech Co., Ltd. Monofunctional branched polyethyleneglycol and bio-related substance modified by same
CN104877127B (zh) * 2015-06-23 2017-11-10 厦门赛诺邦格生物科技股份有限公司 一种八臂聚乙二醇衍生物、制备方法及其修饰的生物相关物质
AU2015342908B2 (en) 2014-11-06 2021-06-24 Pharmaessentia Corporation Dosage regimen for pegylated interferon
US12208142B2 (en) 2017-12-29 2025-01-28 Hoffmann-La Roche Inc. Process for providing PEGylated protein composition
CN111801120A (zh) 2017-12-29 2020-10-20 豪夫迈·罗氏有限公司 用于提供聚乙二醇化蛋白质组合物的方法
PL3731873T3 (pl) * 2017-12-29 2022-04-25 F. Hoffmann-La Roche Ag Sposób dostarczania kompozycji pegylowanego białka

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000109A1 (en) * 1991-06-28 1993-01-07 Genentech, Inc. Method of stimulating immune response using growth hormone
JP3092531B2 (ja) * 1996-11-05 2000-09-25 日本油脂株式会社 コハク酸イミジル基置換ポリオキシアルキレン誘導体の製造方法
ATE375363T1 (de) * 1997-07-14 2007-10-15 Bolder Biotechnology Inc Derivate des wachstumshormons und verwandte proteine
JP3921781B2 (ja) * 1998-02-12 2007-05-30 日本油脂株式会社 カルボキシル基含有ポリオキシアルキレン化合物
AU775937B2 (en) * 1999-01-14 2004-08-19 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
OA13063A (en) * 2001-11-20 2006-11-10 Pharmacia Corp Chemically-modified human growth hormone conjugates.
JP4764630B2 (ja) * 2002-09-09 2011-09-07 ネクター セラピューティックス 水溶性ポリマーアルカナール
JP4412461B2 (ja) * 2002-11-20 2010-02-10 日油株式会社 修飾された生体関連物質、その製造方法および中間体
US7208145B2 (en) * 2002-12-31 2007-04-24 Nektar Therapeutics Al, Corporation Polymeric reagents comprising a ketone or a related functional group
PT2644206T (pt) * 2003-05-23 2019-07-10 Nektar Therapeutics Derivados de peg contendo duas cadeias de peg

Also Published As

Publication number Publication date
NL1029828A1 (nl) 2006-03-01
BRPI0515118A (pt) 2008-07-01
TNSN07078A1 (fr) 2008-06-02
MA28908B1 (fr) 2007-10-01
WO2006024953A3 (en) 2007-01-18
UY29088A1 (es) 2006-03-31
CN101010105A (zh) 2007-08-01
KR20070042567A (ko) 2007-04-23
ZA200701802B (en) 2008-08-27
PE20060654A1 (es) 2006-08-12
EA200700380A1 (ru) 2007-10-26
AP2007003919A0 (en) 2007-02-28
CA2577999A1 (en) 2006-03-09
AU2005278903A1 (en) 2006-03-09
JP2008511610A (ja) 2008-04-17
AR050851A1 (es) 2006-11-29
NO20071322L (no) 2007-05-29
MX2007002441A (es) 2007-05-04
EP1789092A2 (en) 2007-05-30
TW200621291A (en) 2006-07-01
GT200500235A (es) 2006-03-21
CR8942A (es) 2007-08-16
WO2006024953A2 (en) 2006-03-09
IL181085A0 (en) 2007-07-04
NL1029828C2 (nl) 2006-10-20

Similar Documents

Publication Publication Date Title
CR8942A (es) Conjugados de hormona del crecimiento humana y polietilenglicol ramificado con glicerol, proceso para su preparacion y metodos de uso de los mismos.
AR047928A1 (es) Derivados de tetrahidropiridoindol
BR0313343A (pt) Uso de uma mistura de agentes permeantes, soluções para aplicação ungueal e periungueal e uso de uma solução para aplicação ungueal e periungueal
NZ591261A (en) Improvements in the absorption of therapeutic agents across mucosal membranes or the skin
CO6501124A2 (es) Polipeptidos inmunomoduladores derivados se la il 2 y su uso terapeutico en cancer y en infecciones crónicas
AR069903A1 (es) Conjugado anticuerpo- molecula asociada dirigidos a la proteina tirosina quinasa 7 (ptk 7), composicion farmaceutica que lo comprende, acido nucleico, factor de expresion y celula huesped relacionados y su uso para preparar un medicamento util para el tratamiento o prevencion de cancer
BRPI0513508A (pt) conjugados de insulina-oligÈmero, formulações e usos desses
IT1288290B1 (it) Acido ialuronico autoreticolato e relative composizioni farmaceutiche per il trattamento delle artropatie
DK2249869T3 (da) Flydende formulering af FSH
UA91575C2 (ru) Дендример-пег с четырьмя ветвями для коньюгирования с белками и пептидами
CR11648A (es) Composicion que comprende anticuerpo que se fija al dominio ii de her2, y sus variantes acidas
NI201000193A (es) Formulaciones orales de análogos de citidina y métodos de uso de las mismas.
BR0308429A (pt) Aroilpiridinonas monocìclicas como agentes antiinflamatórios
AR060755A1 (es) Formulaciones de inhibidores de dipeptidil peptidasa iv (dpp iv)
CY1111177T1 (el) Ενωση φαινοθειαζινιου για επουλωση τραυματων
BRPI0517500B8 (pt) composto, uso de uma composição, composição farmacêutica, composição cosmética, usos não-terapêuticos de uma composição cosmética e processo cosmético para melhorar a aparência da pele
CL2012000261A1 (es) Composición farmacéutica líquida de ácido 4- {[9-cloro-7-(2-fluoro-6-metoxifenil)-5h-pirimido[5,4-d][2]benzazepin-2-il]amino}-2-metoxibenzoico en una mezcla de disolventes con al menos 15% de propilenglicol, 15% de peg400 y menos de 50% de agua; y su uso para la preparación de un medicamento para el tratamiento de cáncer.
CL2012003038A1 (es) Polietilenglicol conjugado a factor viia; composicion farmacéutica que comprende dicho polietilenglicol conjugado a factor viia; uso de una composicion farmaceutica para tratar enfermedad o trauma de la coagulacion de la sangre en un paciente que la necesita; proceso para preparar el siguiente polietilenglicol conjugado a factor viia.
EA200602137A1 (ru) Гидрогелевые препараты интерферона
BR112012015437A2 (pt) composição tópica substancialmente anidra de armazenamento estável
AR077347A1 (es) Mejoramientos en composiciones farmaceuticas y relacionados con ellas
BRPI0606396A2 (pt) sulfonas tripeptìdicas e tetrapeptìdicas, composição farmacêutica contendo as mesmas, uso relacionado e método de preparação das referidas sulfonas
EA200700976A1 (ru) Соединения в виде молекул-конъюгатов, обладающих повышенной активностью в отношении включения клеткой
ECSP088242A (es) Combinaciones que comprenden dmxaa para el tratamiento de cancer
BR112015022730A2 (pt) formulações de rfviii, método para conjugação covalente de rfviii com um polímero biocompatível e uso de rfviii no preparo de formulação de rfviii para tratamento de hemofilia a